| Autor: |
Pandey K; Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India., Sinha PK, Das VR, Bimal S, Singh SK, Das P |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical medicine. Pathology [Clin Med Pathol] 2009 Jan 23; Vol. 2, pp. 1-4. Date of Electronic Publication: 2009 Jan 23. |
| Abstrakt: |
Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsiveness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine are in the pipe line. Interferon gamma has been used with discouraging results. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
